BRAF and atrial fibrillation: If future studies on larger samples replicate our findings, BRAF V600E AF may prove to be a clinically useful biomarker to guide management decisions for MPTC, particularly in determining the appropriate balance between active surveillance and more aggressive interventions, such as hemi-thyroidectomy, total thyroidectomy, or limited central neck dissection.